NASDAQ:RLAY Relay Therapeutics Q2 2026 Earnings Report $19.39 +0.43 (+2.27%) Closing price 04:00 PM EasternExtended Trading$18.80 -0.59 (-3.06%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Relay Therapeutics EPS ResultsActual EPS-$0.41Consensus EPS -$0.39Beat/MissMissed by -$0.02One Year Ago EPSN/ARelay Therapeutics Revenue ResultsActual Revenue$0.35 millionExpected Revenue$0.96 millionBeat/MissMissed by -$610.00 thousandYoY Revenue GrowthN/ARelay Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time4:00PM ETUpcoming EarningsRelay Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Relay Therapeutics Earnings HeadlinesRelay Therapeutics, Inc. (NASDAQ:RLAY) Stock Has Consensus Price Target of $25.92 According to BrokeragesSeptember 28, 2026 | americanbankingnews.comRelay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 5 at 1:00 AM | Investors Alley (Ad)Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks TranscriptSeptember 10, 2026 | seekingalpha.comRelay Therapeutics CFO Sells 17,717 Shares for $350,000September 2, 2026 | fool.comRelay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside ChatsSeptember 1, 2026 | quiverquant.comQSee More Relay Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email. Email Address About Relay TherapeuticsRelay Therapeutics (NASDAQ:RLAY) is a clinical-stage biotechnology company focused on discovering and developing medicines for diseases driven by genetically defined targets, particularly in oncology. The company uses its proprietary Dynamo platform, which combines structural biology, computational modeling, machine learning and medicinal chemistry to study how proteins move and to identify potential drug-binding sites that may be difficult to address with conventional approaches. Relay’s pipeline has included targeted cancer therapies such as RLY-2608, an investigational oral inhibitor designed to selectively target PI3K-alpha mutations, and RLY-4008 (lirafugratinib), an investigational FGFR2 inhibitor developed for cancers with specific FGFR2 alterations. The company evaluates its candidates through clinical studies and may pursue commercialization and development collaborations as programs advance. Founded in 2016 and headquartered in Cambridge, Massachusetts, Relay Therapeutics conducts research and clinical development activities intended to support the global treatment of cancer and other serious diseases. Sanjiv Patel serves as the company’s president and chief executive officer.View Relay Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
